Skip links

Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat)

Full Name Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat)
Drug Pombiliti & Opfolda
Manufacturer Amicus Therapeutics
Route of Administration Intravenous and oral
Site of Care Home or Healthcare Facility
Approved Indication The treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT)
Disease Pompe Disease
Therapeutic Area Neurology, Genetics
Enrollment Form Link Pombiliti & Opfolda Enrollment Form
Phone Number 800-240-9572
Fax Number 877-220-7581
Product Website